Compare Iron Mountain Inc (IRM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iron Mountain Inc vs TG Therapeutics Inc — how do they compare? Iron Mountain Inc trades at $122.75 (market cap $36.44B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Iron Mountain Inc is far larger — about 4.8× TG Therapeutics Inc's market cap, and Iron Mountain Inc pays a 2.82% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| IRM | TGTX | |
|---|---|---|
Market Cap | $36.44B | $7.64B |
Sector | Real Estate | Health |
52-Week High | $133.06 | $59.06 |
52-Week Low | $78.86 | $26.94 |
Enterprise Value | $55.85B | $7.84B |
Dividend Yield | 2.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $124.55, up 2.46% on the day, with a bearish technical signal but strong recent earnings beats. Revenue growth is robust, reaching $6.90B in 2025, though net margins are thin at 5.54%. The stock shows high valuation multiples, including a P/E of 86.8, and carries significant debt, with total liabilities at $18.94B. Analyst consensus is bullish with a $141.50 price target, supported by institutional buying and positive Q2 2026 results highlighted by data center growth.
Outlook is cautiously optimistic due to earnings momentum and data center expansion, but high debt and declining paper storage pose risks. The stock offers potential upside to the consensus target, yet investors must weigh valuation concerns against operational strengths.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
